Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 280 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed830    
    Printed33    
    Emailed0    
    PDF Downloaded176    
    Comments [Add]    

Recommend this journal

 
ORIGINAL ARTICLE
Year : 2003  |  Volume : 45  |  Issue : 4  |  Page : 234-238

Olanzapine and Fluoxetine Combination In Severe or Resistant Depression


1 Prof, and Head, Dept of Psychiatry, Sir JJ Group of Hospitals, Mumbai, India
2 Prof, and Head, Dept. of Psychiatry, Seth GS Medical College and KEM Hospital, Mumbai, India
3 Associated Professor and Head, Dept. of Psychiatry and Superintendent, Mahatma Gandhi Medical College, Indore, India
4 Consultant Psychiatrist and Psychotherapist, Dr. Contractor's Hospital, Vadodara, India
5 Consultant Psychiatrist, Ramprasad Chambers, Nana Peth, Pune, India
6 Asst. Prof. of Psychiatry, Deccan College of Medical Sciences and Owaisi Hospital.and Research Centre, Hyderabad, India
7 Prof., of Psychiatry, Gandhi Hospital, Secunderabad, India
8 Consultant Psychiatrist, Jehangir Hospital and Medical Centre, Pune, India
9 Clinical Research Associate, MACR, Ranbaxy Laboratories Ltd, India
10 Senior Research Scientist, Clinical Data Management, Ranbaxy Laboratories Ltd, India
11 MACR, Ranbaxy Laboratories Ltd, India

Correspondence Address:
R M Haridas
Prof, and Head, Dept of Psychiatry, Sir JJ Group of Hospitals, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21206864

Rights and PermissionsRights and Permissions

Objective : The purpose of this study was to investigate the efficacy and safety of Fixed Dose Combination (FDC) of olanzapine 5 mg and fluoxetine 20 mg in Indian patients with severe or treatment resistant depression. Design : This was an open, non-comparative study of seven weeks duration with an initial placebo run in period of one week. Method : One hundred and fifty three patients were enrolled. One hundred and forty-four patients completed the study as per protocol and 151 patients were safety evaluable. One hundred and eleven patients (77%) received one tablet of FDC of olanzapine 5 mg / fluoxetine 20 mg once daily for 6 weeks, in patients (14%), the dose was stepped up at the end of 2 weeks to 2 tablets of FDC of olanzapine 5 mg/ fluoxetine 20 mg once daily for a further 4 weeks and 13 patients (9%) required dose to be stepped up at the end of 4 weeks to 3 tablets of FDC of olanzapine 5 mg and fluoxetine 20 mg once daily for last 2 weeks. Results : One hundred and thirty four patients (93%) responded to FDC of olanzapine and fluoxetine therapy (a responder was defined as a patient with 50 % reduction over baseline in HDRS total score at the end of therapy). Statistically significant (p< 0.0001) reductions in HDRS total score, MADRS total score and CGI severity scores were seen with olanzapine/ fluoxetine combination. One hundred and four patients (72%) were remitters (HDRS total score of <7) after 6 weeks of therapy. Adverse experiences were reported by thirty one patients (20.5%). Majority of them were mild in intensity. No serious adverse event was recorded with study therapy. Three patients were withdrawn from the therapy due to adverse event. Conclusion : Treatment with FDC of olanzapine 5 mg / fluoxetine 20 mg was highly effective and well tolerated in Indian patients with severe or treatment resistant depression.



[PDF]*

        

Print this article         Email this article